B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate

Rune A. Høglund, Justyna Polak, Frode Vartdal, Trygve Holmøy, Andreas Lossius

PII: S2211-0348(18)30310-9
DOI: https://doi.org/10.1016/j.msard.2018.08.032
Reference: MSARD 956

To appear in: Multiple Sclerosis and Related Disorders

Received date: 26 April 2018
Revised date: 22 August 2018
Accepted date: 30 August 2018

Please cite this article as: Rune A. Høglund, Justyna Polak, Frode Vartdal, Trygve Holmøy, Andreas Lossius, B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate, Multiple Sclerosis and Related Disorders (2018), doi: https://doi.org/10.1016/j.msard.2018.08.032

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Highlights

- DMF impacts the composition of B cells in the blood and CSF of MS patients
- Treatment with DMF is associated with reduced CSF cell counts
- Treatment with DMF leads to a relative reduction of plasmablasts in the CSF
B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate

Rune A. Høglund¹,²*, Justyna Polak²,³, Frode Vartdal³, Trygve Holmøy¹,², Andreas Lossius¹,³*

¹Department of Neurology, Akershus University Hospital, Lørenskog, Norway
²Institute of Clinical Medicine, University of Oslo, Oslo, Norway
³Department of Immunology and Transfusion Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

*Correspondence:
Andreas Lossius, Department of Neurology, Akershus University Hospital, PO Box 1000, 1478 Lørenskog, Norway. Tel: +47.2307.3814; Fax: +47.2307.3510; E-mail: andreas.lossius@rr-research.no

Rune A. Høglund, Department of Neurology, Akershus University Hospital, PO Box 1000, 1478 Lørenskog. Tel: +47.6796.3957; E-mail: r.a.hoglund@medisin.uio.no

Keywords: multiple sclerosis, B cell, dimethyl fumarate, memory B cell, cerebrospinal fluid, plasmablast

Words (main text): 2249
Figures: 3
Tables: 1
Abstract

Background: B cells may contribute to the immunopathogenesis of multiple sclerosis (MS). Dimethyl fumarate (DMF) has recently been shown to reduce the frequency of memory B cells in blood, but it is not known whether the drug influences the cellular composition in the cerebrospinal fluid (CSF).

Methods: A cross-sectional study examining the cellular composition in blood and cerebrospinal fluid (CSF) from 10 patients treated with DMF and 18 patients receiving other disease modifying drugs or no treatment.

Results: Patients treated with DMF had reduced proportions of memory B cells in blood compared to other MS patients ($p = 0.0007$), and the reduction correlated with treatment duration ($r_s = -0.75, p = 0.021$). In the CSF, the absolute number of mononuclear cells were significantly lower in DMF-treated patients compared to the other patients ($p = 0.023$), and there was a disproportionate decrease of plasmablasts ($p=0.031$).

Conclusion: The results of this exploratory study support a B-cell mediated mechanism of action for DMF in both blood and CSF.
1 Introduction

B cells have an important role in multiple sclerosis (MS), as is evident from several successful clinical trials of B-cell depletion\textsuperscript{1-3}. Several potential mechanisms have been proposed, including antigen presentation, cytokine secretion, and antibody production\textsuperscript{4}. In MS, the proportion of immunoglobulin class-switched CD27\textsuperscript{+} B cells is increased in the cerebrospinal fluid (CSF) compared to the peripheral blood\textsuperscript{5}, and in particular the frequency of plasmablasts expressing CD38 and CD138 have been shown to be elevated\textsuperscript{6,7}. Studies have demonstrated that immunoglobulin class-switched B cells in the CSF are related to B cells in the brain parenchyma\textsuperscript{8}, cervical lymph nodes\textsuperscript{9}, and peripheral blood\textsuperscript{10,11}, indicating a dynamic exchange between these compartments.

Dimethyl fumarate (DMF) is an oral disease-modifying treatment (DMT) approved for treating relapsing-remitting MS (RRMS). The mechanism of action is not fully clarified\textsuperscript{12}, but includes a reduction of peripheral blood CD19\textsuperscript{+}CD27\textsuperscript{+} memory B cells\textsuperscript{13-16}. Upon intake, DMF is rapidly metabolized to monomethyl fumarate (MMF), which crosses the blood-brain barrier in animal models and in humans, however only at 15\% of plasma concentration\textsuperscript{17,18}.

The penetration of MMF into the CSF, and the exchange of B cells between the periphery, CSF and the central nervous system (CNS), suggest the possibility that DMF may exert a direct or indirect effect on intrathecal B cells. To address this, we examined blood and CSF B-cell subsets from MS patients treated with DMF and patients not receiving immunomodulatory treatment. We found that while DMF treatment is associated with a decrease of CD19\textsuperscript{+}CD27\textsuperscript{+} memory B cells in the periphery, it is associated with a significant reduction of CD19\textsuperscript{+}CD27\textsuperscript{+}CD38\textsuperscript{+} plasmablasts in CSF.
2 Materials and methods

2.1 Patients

MS patients \((n = 28)\) were recruited at the Departments of Neurology at Akershus University Hospital and Oslo University Hospital; other data based on the same cohort have been previously published \(^\text{19}\). All patients met the 2010 McDonalds criteria for MS \(^\text{20}\), one patient was classified as secondary progressive MS and the remaining as RRMS. All patients had intrathecal synthesis of immunoglobulin G (IgG) at the time of diagnosis, detected as oligoclonal IgG bands by isoelectric focusing. Lumbar puncture was performed either as a part or outside of diagnostic investigations, reflected by the variation in disease duration (Table 1). The study was approved by the Regional Ethical Committee South East (2009/23 S-04143a). All patients gave written informed consent before inclusion.

2.2 Cell subset analysis

For each individual included in this study, blood, serum and CSF samples were collected once, during the same consultation. Blood and CSF mononuclear cells were isolated as described previously, counted using a Neubauer improved hemocytometer, and immediately processed for flow cytometry, which was performed within two hours after sample collection \(^\text{11, 19}\). For B-cell subset identification we used fluorochrome-conjugated antibodies as described \(^\text{19}\), including anti-human CD19, CD27, CD38, CD138, IgG, Ki-67, and HLA-DR, and additionally CD3 and CD14 for dump-channel purposes (BD Biosciences). Paired cell samples from CSF and blood were stained for surface antigens, and after fixation and permeabilization following the manufacturer’s instructions (Fixation/Permeabilization Solution Kit, BD Biosciences), the cells were stained for Ki-67. The flow cytometry dataset was reanalyzed for the present study using FlowJo Version 10.2 (FlowJo, LLC). Of note, flow
cytometry data from one DMF-treated and one untreated patient were excluded due to technical reasons.

2.3 Quantification of IgG and albumin

For each patient, blood and CSF were collected simultaneously. After centrifugation and removal of cells for immediate flow cytometry analysis, the serum and CSF supernatants were frozen at -80° C. The supernatants were thawed and analyzed as a single batch within 36 months after the collection and freezing of the first patient sample. The collection and freezing procedures followed the published consensus protocol for the standardization of cerebrospinal fluid collection and biobanking \(^{21}\). IgG and albumin in CSF were quantified by nephelometry (BN ProSpec Systems, Siemens). IgG and albumin in serum were determined by turbidimetry and colorimetry, respectively (Vitros 5.1 FS, Ortho Clinical Diagnostics).

2.4 Statistics

Statistical analyses were performed in JMP® pro 12.1 (StataCorp, LLC). Due to non-normality of data, non-parametric 2-sample Wilcoxon exact tests were used to compare groups unless otherwise specified. The significance level was set at 5%, and the tests were two-sided. No correction for multiple testing was performed. Results are presented as median [range]. Figures were made in FlowJo and JMP pro 12.1.

3 Results

3.1 Patients

Ten patients received treatment with DMF at inclusion, whereas 18 received other DMTs or no treatment (seven patients received glatiramer acetate, four received teriflunomide, and seven received no treatment). Clinical and demographic data at the time of CSF and blood
(including serum) collection are shown in Table 1. With the exception of treatment durations, which was shorter for the patients treated with DMF than other DMTs, there were no significant differences in clinical characteristics between DMF-treated patients and the other patients. All DMF-treated patients had normal total lymphocyte count before treatment start, with a median value of $1.7 \times 10^9/L$ [1.2–2.6], and two patients developed lymphopenia during DMF treatment ($<0.9 \times 10^9/L$).  

### 3.2 DMF-treatment is associated with lower numbers of mononuclear cells in the CSF

DMF-treated patients had lower total CSF mononuclear cell counts compared to the other patients (560/mL [80–3000] vs 680/mL [264–6736], $p=0.023$). Similar results were obtained when comparing DMF-treated patients to those not receiving any treatment (Fig S1 A). The CSF mononuclear cell count in DMF-treated patients tended to correlate inversely with the treatment duration, but this was not statistically significant (Spearman $r_s -0.6$, $p=0.07$).

### 3.3 DMF reduces the frequency of memory B cells in blood and plasmablasts in the CSF

Previous studies have shown that DMF reduces the number of memory B cells in blood, typically identified as CD19$^+$CD27$^+$ cells. To identify these cells in blood and CSF, a gating strategy based on available data was devised (Figure 1). Confirming previous studies, we found that DMF-treatment was associated with a relative reduction in CD19$^+$CD27$^+$CD38$^-$ memory B cells in blood (12.8% [2.2–25.2] in DMF-treated vs 26.6% [6.9–46.6] in the other MS patients, $p=0.0007$, Figure 2A). Moreover, the reduction correlated strongly with treatment duration ($r_s = -0.75$, $p=0.021$, Figure 2B). There were no significant differences between the two groups in the proportions of CD19$^+$CD27$^+$CD38$^+$ plasmablasts in blood (Figure 2A). In the CSF, in contrast, there was a selective depletion of CD19$^+$CD27$^+$CD38$^+$ plasmablasts among DMF-treated patients (0% [0–13.6] vs 5.4% [0–69.8], $p=0.031$, Figure
2A), whereas the relative proportion of CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>-</sup> memory B cells was similar in both groups (68.9% [0–100] in DMF-treated vs 66.7% [17.4–80] in other MS-patients, 
\( p=0.534 \), Figure 2A). There were no differences between the two groups in the proportion of total CD19<sup>+</sup> B cells in blood or CSF (Figure 2A). Including only DMF-treated and untreated patients in the analyses yielded similar results (Fig. S1 B).

3.4 DMF reduces HLA-DR expression among memory B cells in blood

To further characterize the B-cell subsets, we examined antigen-presenting potential (HLA-DR), IgG expression, proliferation status (Ki-67), and the expression of the differentiation marker CD138. In patients treated with DMF, we found that blood CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>-</sup> memory B cells express lower levels of the HLA class II molecule HLA-DR (median fluorescence intensity (MFI) 2025 [1702–2410] vs 2279 [1360–3649], \( p=0.04 \), Figure 3). The majority of blood plasmablasts expressed Ki-67 and IgG, and there were no significant differences between the patient groups (Figure 3). We found overall low levels of CD138 expression among blood plasmablasts.

In the CSF, the HLA-DR expression among CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>-</sup> memory B cells was similar in both groups (MFI 1634 [1337–2391] vs 1570 [666–2414], \( p=0.68 \)). Virtually all intrathecal CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup> plasmablasts in both patient groups expressed Ki-67 and the majority expressed IgG (100% [83.3–100] vs 100% [50–100], Figure 3). In most patients in both groups we found that CSF plasmablasts expressed moderate to high levels of CD138 (MFI 1223 [-392–2998] vs MFI 5437 [-142–2091]). There were no significant differences for these variables between the patient groups (Figure 3).
3.5 DMF treatment did not influence intrathecal IgG production
Since DMF-treated patients exhibited preferential reductions of CD19^+CD27^+CD38^+ antibody-secreting cells in CSF, we compared the intrathecal IgG production among DMF-treated patients (n = 10) with that among untreated patients (n = 7). There were no differences in IgG or albumin levels or indices of these, also indicating a similar blood-brain barrier integrity (Table 1).

4 Discussion
This cross-sectional study demonstrates that while DMF-treatment causes a time-dependent reduction in CD19^+CD27^+CD38^+ memory B cells in blood, it leads to a depletion of CD19^+CD27^+CD38^+ plasmablasts in the CSF. Our findings in blood are in agreement with recent publications 13-16, and the present work demonstrates how the peripheral effects of DMF translate into the CSF. These data point to a possible B-cell mediated mechanism of action for DMF, in addition to the previously discussed pluripotent immunomodulatory effects 12.

The almost immediate effect of anti-CD20 treatment in MS is thought to be mediated by a reduction of B cells participating in antigen presentation and/or cytokine production 22, 23. Accordingly, the intrathecal IgG production does not seem to be affected by the treatment in the short run 1, 24. Memory B cells express HLA class II molecules and are potent antigen-presenting cells 25. Interestingly, we found that blood CD19^+CD27^+CD38^+ memory B cells express lower levels of HLA-DR in DMF-treated than in untreated MS patients, suggesting that memory B cells in these patients are less efficient in presenting antigens. One could speculate that a reduced amount of memory B cells, with additionally reduced expression of HLA class II molecules, may result in less maturation and development of
CD19⁺CD27⁺CD38⁺ antibody-secreting cells in the CSF. This possibility is supported by the dynamic exchange of B cells between the CSF and periphery. However, a not mutually exclusive possibility is that the observed alterations in the composition of CSF B cells could be due to a local intrathecal effect of MMF.

Despite depletion of CD19⁺CD27⁺CD38⁺ plasmablasts in the CSF of DMF-treated patients, we did not observe a reduced intrathecal IgG production. This could be due to persistent secretion from end-differentiated plasma cells protected within tertiary lymphoid tissue in the meninges of MS patients. In line with this thought, we found that all antibody-secreting cells in the CSF express high levels of Ki-67, compatible with recently derived proliferating plasmablast. Interestingly, a similar persistence of intrathecal IgG synthesis has been observed in patients receiving anti-CD20 therapies. In accordance with the present findings, no difference in circulating IgG, IgA, or IgM in blood of DMF treated patients has been observed, indicating that end differentiated plasma cells could be protected from the effects of the drug also in the periphery in a short-term perspective.

The strength of this study is the comparison of CSF B-cell subsets between two groups of MS patients similar in clinical and demographic characteristics. This was made possible by slight different treatment strategies between the two clinical departments contributing to the study. Samples from both hospitals were transported directly to the same external laboratory and processed identically, and the findings are not influenced by differences in inflammatory activity. Although we cannot exclude that differences in treatment durations could have influenced the results, treatment durations were long enough to allow full immunological effect in the majority of patients receiving DMF and other DMTs.
This study has several limitations. First, the number of patients is small. Given the risk of lumbar puncture headache, as well as rare but more serious risks such as infection, bleeding and herniation, we cannot perform lumbar puncture solely for the purpose of studying drug effects. While properly understanding the mechanism of action of DMF in MS patients is important, such studies must due to the above reasons be part of studies on disease mechanisms, which was the primary aim of this study \(^{19}\). This is therefore an exploratory study, the p-values were not corrected for multiple testing, and the results need to be reproduced in an independent study. Second, the control group is heterogeneous from a treatment standpoint, which potentially could confound our results. Nevertheless, as the sub-analysis with untreated controls \((n = 7)\) demonstrated similar results, and lymphocyte depletion and reduced memory B-cell population in blood are analogue to previous reports \(^{13-16}\), we believe our findings have merit. While reduction in blood plasmablasts similar to what we observed in CSF have not been extensively described, a recent interim analysis of the PROCLAIM study demonstrated a decline in blood plasmablasts that had a delayed onset compared to memory B cell depletion \(^{28}\). This delay, in addition to the relatively low proportions of circulating plasmablasts in blood compared to CSF of MS patients can potentially have hidden this phenomenon in studies with shorter time-frames. Lastly, as our data did not contain markers for IgD, we were unable to differentiate between class-switched and unswitched memory B cells. A recent publication limited to blood found that both populations are affected similarly, with a corresponding increase in CD27 IgD\(^+\) naïve B cells \(^{29}\). New studies as to how these subpopulations are distributed in the CSF could also enlighten whether the effects of DMF are mainly peripheral or intrathecal.
5 Conclusion

This is the first study on the effects of DMF treatment on B cells in CSF, suggesting that while memory B cells are reduced in blood, plasmablasts are preferentially depleted in CSF. These findings, which need to be verified in an independent study, support the hypothesis that DMF mediates positive effects through B-cell modulation.

Abbreviations

CSF – cerebrospinal fluid
DMT – disease modifying therapy
IgG – immunoglobulin G
M/DMF – mono-/dimethyl fumarate
MFI – median fluorescence intensity
MS – multiple sclerosis
RRMS – relapsing remitting MS
TFM - teriflunomide

Funding

The study was supported by the South-Eastern Norway Regional Health Authority (grant 2016079) and the Norwegian Research Council (grant 250864/F20).

Declaration of conflicting interests

RH has received speaker honoraria from Merck and Roche, and unrestricted research grants from Biogen and Novartis. TH has received unrestricted research grants or speaker honoraria from Biogen, Merck, Novartis, Sanofi Genzyme and Teva. AL has received speaker honoraria
from Roche, and unrestricted research grants from Sanofi Genzyme. JP and FV declare no conflict of interest.

Author contributions

Study concept and design: AL, FV, RH, TH; data acquisition and/or analysis: AL, JP, RH; drafting the manuscript AL, RH. All authors revised the manuscript for intellectual content.

References

1. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *The New England journal of medicine* 2017; 376: 221-234. 2016/12/22. DOI: 10.1056/NEJMoa1601277.

2. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. *Lancet (London, England)* 2011; 378: 1779-1787. 2011/11/04. DOI: 10.1016/s0140-6736(11)61649-8.

3. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. *Annals of neurology* 2008; 63: 395-400. 2008/04/03. DOI: 10.1002/ana.21363.

4. Lehmann-Horn K, Kinzel S and Weber M. Deciphering the Role of B Cells in Multiple Sclerosis—Towards Specific Targeting of Pathogenic Function. *International Journal of Molecular Sciences* 2017; 18: 2048.

5. Hauser SL. Clinical trials and role of B-cell depletion therapy in relapsing-remitting MS. ECTRIMS 2016: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2016 Sept 16; London, UK (2016). 147324
6. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. *Brain: a journal of neurology* 2005; 128: 1667-1676. 2005/04/01. DOI: 10.1093/brain/awh486.

7. Kowarik MC, Grummel V, Wemlinger S, et al. Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. *Journal of neurology* 2014; 261: 130-143. 2013/10/29. DOI: 10.1007/s00415-013-7145-2.

8. Obermeier B, Lovato L, Mentele R, et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. *Journal of neuroimmunology* 2011; 233: 245-248. 2011/03/01. DOI: 10.1016/j.jneuroim.2011.01.010.

9. Stern JN, Yaari G, Vander Heiden JA, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. *Science translational medicine* 2014; 6: 248ra107. 2014/08/08. DOI: 10.1126/scitranslmed.3008879.

10. von Budingen HC, Kuo TC, Sirota M, et al. B cell exchange across the blood-brain barrier in multiple sclerosis. *The Journal of clinical investigation* 2012; 122: 4533-4543. 2012/11/20. DOI: 10.1172/jci63842.

11. Johansen JN, Vartdal F, Desmarais C, et al. Intrathecal BCR transcriptome in multiple sclerosis versus other neuroinflammation: Equally diverse and compartmentalized, but more mutated, biased and overlapping with the proteome. *Clinical immunology (Orlando, Fla)* 2015; 160: 211-225. 2015/06/10. DOI: 10.1016/j.clim.2015.06.001.

12. Deeks ED. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. *Drugs* 2016; 76: 243-254. journal article. DOI: 10.1007/s40265-015-0528-1.

13. Smith MD, Martin KA, Calabresi PA, et al. Dimethyl fumarate alters B-cell memory and cytokine production in MS patients. *Annals of clinical and translational neurology* 2017; 4: 351-355. 2017/05/12. DOI: 10.1002/acn3.411.
14. Longbrake EE, Cantoni C, Chahin S, et al. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2017: 1352458517707069. 2017/05/10. DOI: 10.1177/1352458517707069.

15. Li R, Rezk A, Ghadiri M, et al. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. *Journal of immunology (Baltimore, Md : 1950)* 2017; 198: 691-698. 2016/12/16. DOI: 10.4049/jimmunol.1601649.

16. Lundy SK, Wu Q, Wang Q, et al. Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. *Neurology(R) neuroimmunology & neuroinflammation* 2016; 3: e211. 2016/03/24. DOI: 10.1212/nxi.0000000000000211.

17. Edwards K, Penner N, Rogge M, et al. A pharmacokinetic study of delayed-release dimethyl fumarate to evaluate cerebrospinal fluid penetration in patients with secondary progressive multiple sclerosis. ePosters EP1501. *Multiple Sclerosis Journal* (2016) 22(3_suppl):706-827. doi: 10.1177/1352458516663067.

18. Penner N, Zhu B, Woodward C, et al. Penetration of dimethyl fumarate into cerebrospinal fluid and brain: a pharmacokinetic and tissue distribution study in monkeys. Poster Session 1, P672. *Multiple Sclerosis Journal* (2016) 22(3_suppl):88-399. doi: 277 10.1177/1352458516663081.

19. Lossius A, Tomescu-Baciu A, Holmoy T, et al. Selective intrathecal enrichment of G1m1-positive B cells in multiple sclerosis. *Annals of clinical and translational neurology* 2017; 4: 756-761. 2017/10/20. DOI: 10.1002/acn3.451.

20. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Annals of neurology* 2011; 69: 292-302. 2011/03/10. DOI: 10.1002/ana.22366.
21. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73(22): 1914-22. 2009/11/30 DOI: 10.1212/WNL.0b013e3181c47cc2.

22. Funaro M, Messina M, Shabbir M, et al. The role of B cells in multiple sclerosis: more than antibodies. Discovery medicine 2016; 22: 251-255. 2016/12/24.

23. Kinzel S and Weber MS. B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence. CNS drugs 2016; 30: 1137-1148. 2016/11/16. DOI: 10.1007/s40263-016-0396-6.

24. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. Journal of neuroimmunology 2006; 180: 63-70. 2006/08/15. DOI: 10.1016/j.jneuroim.2006.06.029.

25. Kurosaki T, Kometani K and Ise W. Memory B cells. Nature reviews Immunology 2015; 15: 149-159. 2015/02/14. DOI: 10.1038/nri3802.

26. Pikor NB, Prat A, Bar-Or A, et al. Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity. Frontiers in immunology 2016; 6. Mini Review. DOI: 10.3389/fimmu.2015.00657.

27. Hauser SL. The Charcot Lecture | beating MS: a story of B cells, with twists and turns. Multiple sclerosis (Houndmills, Basingstoke, England) 2015; 21: 8-21. 2014/12/07. DOI: 10.1177/1352458514561911.

28. von Hehn C, Mehta D, Prada C, et al. Interim Results of an Open-label Study to Assess the Effects of Delayed-release Dimethyl Fumarate on Lymphocyte Subsets and Immunoglobulins in Patients With Relapsing-Remitting Multiple Sclerosis. Poster 380 presented at American Academy of Neurology - 69th Annual Meeting, Session P5, MS and CNS Inflammatory Disease, April 27, 2017)
29. Nakhaei-Nejad M, Barilla D, Lee C-H, et al. Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. *Neurology – Neuroimmunology & Neuroinflammation* 2018; 5. DOI: 10.1212/nxi.0000000000000432.
Table 1 Demographic and clinical characteristics of patients.

| Treatment                  | DMF          | Other        | Statistical test  |
|----------------------------|--------------|--------------|-------------------|
| Participants               | 10           | 18           | -                 |
| Age (years)                | 41 (27–58)   | 47.5 (25–57) | p=0.75<sup>1</sup> |
| Sex (M/F)                  | 4/6          | 5/13         | p=0.68<sup>2</sup> |
| Disease duration (months)  | 47.5 (10–153)| 102 (2–283)  | p=0.10<sup>1</sup> |
|                            | 8 (2–13)     | All: 35 (3–152)* | p=0.0012<sup>1</sup> |
| Treatment duration (months)| GA: 79 (18–152) | TFM: 12.5 (3–27) |                 |
| EDSS score                 | 1.25 (1–3.5) | 1.25 (0–5.5) | p=0.78<sup>1</sup> |
| Number of relapses         | 1.5 (1–5)    | 3 (1–6)      | p=0.11<sup>1</sup> |
| Time since last relapse (months) | 18.5 (2–118) | 5 (1–164)    | p=0.60<sup>1</sup> |
| Albumin ratio**            | 4.4 (3.6–9.24)| 4.6 (2.3–6.9) | p=0.67<sup>1</sup> |
| IgG index**                | 0.7 (0.5–2.1) | 1.2 (0.5–1.9) | p=0.74<sup>1</sup> |

Numbers given as median (range). DMF: dimethyl fumarate. EDSS: expanded disability status scale. GA: glatiramer acetate. MRI: magnetic resonance imaging. TFM: teriflunomide. 
<sup>1</sup>Wilcoxon 2-sample exact test, <sup>2</sup>Fishers exact test. *untreated patients excluded **compared between DMF treated and no-treated
Figure legends

Figure 1 - Gating strategy

We devised a gating strategy to identify single lymphocytes expressing CD19, CD27, CD38, CD138, HLA-DR, IgG and/or Ki-67. Cells expressing CD3 or CD14 were excluded in a dump channel.
Figure 2 - DMF preferentially reduces the frequency of memory B cells in blood and plasmablasts in the CSF

(A) Proportion of CD19+CD27+CD38− memory B cells and CD19+CD27+CD38+ plasmablasts of CD19+ B cells, and proportion of CD19+ B cells of lymphocytes in blood and CSF. Each symbol represents the cell frequencies in a given individual, and the bars depict the median.

(B) Proportion of memory B cells in DMF treated patients, in linear fit with treatment duration (boundaries depict 95% confidence interval). DMF, dimethyl fumarate; GA, glatiramer acetate; TFM, teriflunomide.
Figure 3 - DMF reduces HLA-DR expression among memory B cells in blood

MFI of HLA-DR for CD19^+CD27^+CD38^- memory B cells, proportion of CD19^+CD27^+CD38^- plasmablasts expressing Ki-67 and IgG, and MFI of CD138 for plasmablasts. Each symbol represents the cell frequencies or MFI in a given individual, and the bars depict the median.

DMF, dimethyl fumarate; GA, glatiramer acetate; TFM, teriflunomide.
Supplementary Figure – Sub analysis of DMF vs untreated patients for B cell subsets in blood and CSF

(A) Number of mononuclear cells per mL of cerebrospinal fluid from patients treated with DMF or no disease modifying therapy. (B) Proportion of CD19^+CD27^+CD38^- memory B cells and CD19^+CD27^+CD38^+ plasmablasts of CD19^+ B cells, and proportion of CD19^+ B cells of lymphocytes in blood and CSF. Each symbol represents the cell count or frequencies in a given individual and the bars depict the median. DMF, dimethyl fumarate.